Cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are a few symptoms of cardiometabolic diseases. Individuals suffering from cardiometabolic syndrome are prone to many other life-threatening diseases, such as type 2 diabetes, stroke, coronary artery disease (CAD), and cardiovascular disease (CVD). Both genetic and environmental conditions are responsible for the development of the diseases.
The cardiometabolic diseases market growth is mainly attributed to factors such as increasing prevalence of cardiometabolic diseases and innovation in CMDs therapeutics. However, underdiagnosisof CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market.
Cardiometabolic diseases (CMDs) are one of the leading causes of death worldwide. These diseases are mainly caused by an unhealthy lifestyle, physical inactivity, smoking, and an unhealthy diet. CMDs include cardiovascular diseases (CVDs), diabetes mellitus, and chronic renal failure. As per the WHO, around 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.
Most cardiovascular diseases can be prevented by addressing behavioral risk factors, such as tobacco intake, unhealthy dietary choices, obesity, physical inactivity, and alcohol consumption. Diabetes is one of the life-threatening chronic diseases with no functional cure. It leads to various complications and increases the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As per the International Diabetes Federation (IDF), in 2019, ~463 million adults were living with diabetes, which is expected to reach 700 million by 2045.
There is a global rise in the number of people having one or more CMDs due to increasing smoking, lack of exercise, alcohol consumption, and unhealthy food habits. As per the WHO July 2021 stats, more than 8 million people die every year due to tobacco consumption. Its consumption is higher in low- and middle-income countries, with 80% of its global consumer base living in these countries. The increasing prevalence of obesity is giving rise to the patient base suffering from CMDs as well. With this rapid upswing in the prevalence of CMDs, the need for appropriate cardiometabolic disease treatments has skyrocketed, resulting in tremendous growth of the market.
The cardiometabolic diseases market, by type, is segmented into cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. The cardiovascular disease (CVD) segment held the largest share of the market in 2021, and the segment is anticipated to register the highest CAGR in the market during the forecast period.
By treatment, the cardiometabolic diseases market is segmented into ACE inhibitors, diuretics, Glucophage, and others. The ACE inhibitors segment held the largest share of the market in 2021, and the same segment is anticipated to register the highest CAGR in the market during the forecast period.
The cardiometabolic diseases market, by dosage, is bifurcated into tablet and injection. The tablet segment held a larger market share in 2021 and is anticipated to register a higher CAGR in the market during the forecast period.
The cardiometabolic diseases market, by route of administration, is bifurcated into oral and intravenous. In 2021, the oral segment held a larger share of the market and is expected to register a higher CAGR in the coming years.
The cardiometabolic diseases market, by end users, is segmented into clinic, hospital, and homecare setting. In 2021, the hospital segment held the largest share of the market and is anticipated to register the highest CAGR in the market during the forecast period.
Product launches and approvals are commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the laboratory developed test market players focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name globally.
Based on type, the cardiometabolic diseases market is segmented into cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. Based on treatment, the market is segmented into ACE inhibitors, diuretics, Glucophage, and others. Based on dosage, the cardiometabolic diseases market is bifurcated into tablet and injection. Based on route of administration, the market is bifurcated into oral and intravenous. Based on end users, the cardiometabolic diseases market is segmented into clinic, hospital, and homecare setting. By geography, the market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East and Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).
The regional trends and factors influencing the Cardiometabolic Diseases Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Cardiometabolic Diseases Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 93.49 Billion |
| Market Size by 2028 | US$ 121.8 Billion |
| Global CAGR (2021 - 2028) | 3.9% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Cardiometabolic Diseases Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Cardiometabolic Diseases Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The List of Companies - Cardiometabolic Diseases Market
The global cardiometabolic diseases market cardiovascular disease (CVD), hypertension, type 2 diabetes, and obesity. The cardiovascular disease (CVD) segment is expected to hold the largest share and register the highest CAGR in the market during the forecast period.
The cardiometabolic diseases market majorly consists of the players such as as Eli Lilly and Company; Bayer AG; Arrowhead Pharmaceuticals, Inc; Novartis AG; Boehringer Ingelheim International GmbH; Novo Nordisk A/S; AstraZeneca; Alnylam Pharmaceuticals, Inc.; Cardax, Inc.; and Kowa Company, Ltd among others.
The factors that are driving and restraining factors that will affect cardiometabolic diseases market in the coming years. Factors such as increasing prevalence of cardiometabolic diseases and innovation in CMDs therapeutics. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) is hampering the growth of the market.
Cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are a few symptoms of cardiometabolic diseases. Individuals suffering from cardiometabolic syndrome are prone to many other life-threatening diseases, such as type 2 diabetes, stroke, coronary artery disease (CAD), and cardiovascular disease (CVD). Both genetic and environmental conditions are responsible for the development of the diseases.